Aristotelis Nastos is a venture capital investor specializing in life sciences. He is Managing Partner at BiomedVC, a Swiss-based Biotech-focused VC fund, where he focuses on building and backing breakthrough companies that translate cutting-edge science into transformative therapies. He partners closely with founders from early-stage investment through global scaling, supporting strategy, financing, and corporate development.

Aristotelis has served on the boards of several biotechnology companies like Emergence Therapeutics (acquired by Lilly), Rigontec (acquired by MSD), CEVEC (acquired by Cytiva), Scienion (acquired by Cellink/BICO), and Direvo (acquired by Bayer). Previously, he also held senior investment roles, including Head of Life Sciences at NRW-BANK and was Partner at Creathor Ventures, where he also focused on early-stage investments in life sciences.

His academic career includes a Master in Biology and a PhD in Cell Biology. He did a PostDoc at King’s College in London supported by an International Research Fellowship of the Wellcome Trust before he became Head of a Research Group at the University Hospital in Düsseldorf, Germany.